Long-Term Sex-Biased Correction of Circulating Propionic Acidemia Disease Markers by Adeno-Associated Virus Vectors

Human Gene Therapy

Volumn 26, Issue 3, 2015, Pages 153-160

  Guenzel, Adam J ^a   Collard, Renata ^b   Kraus, Jan P ^b   Matern, Dietrich ^c   Barry, Michael A ^c  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 10; ADENO ASSOCIATED VIRUS 8 VECTOR; BIOLOGICAL MARKER; CITRIC ACID; LUCIFERASE; METHYL CITRATE; PARVOVIRUS VECTOR; PROPIONYL COENZYME A CARBOXYLASE; PROPIONYL COENZYME A CARBOXYLASE ALPHA; PROPIONYLCARNITINE; UNCLASSIFIED DRUG; 2-METHYLCITRIC ACID; CARNITINE; METHYLMALONYL COENZYME A DECARBOXYLASE;

ADENO ASSOCIATED VIRUS 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE; GENE EXPRESSION; GENE THERAPY; HEART; LIVER; MALE; MOUSE; NONHUMAN; PCCA GENE; PCCB GENE; PHENOTYPE; PROPIONIC ACIDEMIA; PROTEIN EXPRESSION; SEX DIFFERENCE; SKELETAL MUSCLE; TISSUE DISTRIBUTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SEXUAL DEVELOPMENT;

ADENO-ASSOCIATED VIRUS; MUS;

ANIMALS; BIOMARKERS; CARNITINE; CITRATES; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; LIVER; LUCIFERASES; MALE; METHYLMALONYL-COA DECARBOXYLASE; MICE; MUSCLE, SKELETAL; PROPIONIC ACIDEMIA; REAL-TIME POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS;

EID: 84924971925     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.126     Document Type: Article

References (46)

1. Hsia YE, Scully KJ, Rosenberg LE. Inherited propionyl-Coa carboxylase deficiency in "ketotic hyperglycinemia." J Clin Invest 1971;50:127-130.
2. Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis 2014;9:130.
3. Pena L, Franks J, Chapman KA, et al. Natural history of propionic acidemia. Mol Genet Metab 2012;105:5-9.
4. Pettenuzzo LF, Schuck PF, Fontella F, et al. Ascorbic acid prevents cognitive deficits caused by chronic administration of propionic acid to rats in the water maze. Pharmacol Biochem Behav 2002;73:623-629.
5. Kolker S, Burgard P, Sauer SW, et al. Current concepts in organic acidurias: understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis 2013;36:635-644.
6. Schwab MA, Sauer SW, Okun JG, et al. Secondary mitochondrial dysfunction in propionic aciduria: a pathogenic role for endogenous mitochondrial toxins. Biochem J 2006;398:107-112.
7. Ah Mew N, Mccarter R, Daikhin Y, et al. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics 2010;126:e208-e214.
8. Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res 2008;64:213-217.
9. Sperl W, Murr C, Skladal D, et al. Odd-numbered long-chain fatty acids in propionic acidaemia. Eur J Pediatr 2000;159:54-58.
10. Cheema-Dhadli S, Leznoff CC, Halperin ML. Effect of 2-methylcitrate on citrate metabolism: implications for the management of patients with propionic acidemia and methylmalonic aciduria. Pediatr Res 1975;9:905-908.
11. Turgeon CT, Magera MJ, Cuthbert CD, et al. Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. Clin Chem 2010;56:1686-1695.
12. Brandt IK, Hsia YE, Clement DH, et al. Propionicacidemia (ketotic hyperglycinemia): dietary treatment resulting in normal growth and development. Pediatrics 1974;53:391-395.
13. Touati G, Valayannopoulos V, Mention K, et al. Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. J Inherit Metab Dis 2006;29:288-298.
14. Yannicelli S, Acosta PB, Velazquez A, et al. Improved growth and nutrition status in children with methylmalonic or propionic acidemia fed an elemental medical food. Mol Genet Metab 2003;80:181-188.
15. Sutton VR, Chapman KA, Gropman AL, et al. Chronic management and health supervision of individuals with propionic acidemia. Mol Genet Metab 2012;105:26-33.
16. Thompson GN, Chalmers RA. Increased urinary metabolite excretion during fasting in disorders of propionate metabolism. Pediatr Res 1990;27:413-416.
17. Rela M, Muiesan P, Andreani P, et al. Auxiliary liver transplantation for metabolic diseases. Transplant Proc 1997;29:444-445.
18. Schlenzig JS, Poggi-Travert F, Laurent J, et al. Liver transplantation in two cases of propionic acidaemia. J Inherit Metab Dis 1995;18:448-461.
19. Yorifuji T, Muroi J, Uematsu A, et al. Living-related liver transplantation for neonatal-onset propionic acidemia. J Pediatr 2000;37:572-574.
20. Yorifuji T, Kawai M, Mamada M, et al. Living-donor liver transplantation for propionic acidaemia. J Inherit Metab Dis 2004;27:205-210.
21. Barshes NR, Vanatta JM, Patel AJ, et al. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review. Pediatr Transplant 2006;10:773-781.
22. Guenzel AJ, Hofherr SE, Hillestad M, et al. Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. Mol Ther 2013;21:1316-1323.
23. Miyazaki T, Ohura T, Kobayashi M, et al. Fatal propionic acidemia in mice lacking propionyl-CoA carboxylase and its rescue by postnatal, liver-specific supplementation via a transgene. J Biol Chem 2001;276:35995-35999.
24. Campeau E, Desviat LR, Leclerc D, et al. Structure of the PCCA gene and distribution of mutations causing propionic acidemia. Mol Genet Metab 2001;74:238-247.
25. Guenzel AJ, Kraus JP, Matern D, et al. Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors. Hum Gene Ther 2014 [Epub ahead of print].
26. Lock M, Alvira M, Vandenberghe LH, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 2010;21:1259-1271.
27. Turgeon C, Magera MJ, Allard P, et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 2008:54:657-664.
28. Jiang H, Rao KS, Yee VC, et al. Characterization of four variant forms of human propionyl-CoA carboxylase expressed in Escherichia coli. J Biol Chem 2005;280:27719-27727.
29. Chandler RJ, Chandrasekaran S, Carrillo-Carrasco N, et al. Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia. Hum Gene Ther 2011;22:477-481.
30. Hofherr SE, Senac JS, Chen CY, et al. Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy. Hum Gene Ther 2009;20:169-180.
31. Davidoff AM, Ng CY, Zhou J, et al. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 2003;102:480-488.
32. Paneda A, Vanrell L, Mauleon I, et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther 2009;20:908-917.
33. Dane AP, Cunningham SC, Graf NS, et al. Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation. Mol Ther 2009;17:1548-1554.
34. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
35. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 2013;339:1084-1088.
36. De Keyzer Y, Valayannopoulos V, Benoist JF, et al. Multiple OXPHOS deficiency in the liver, kidney, heart, and skeletal muscle of patients with methylmalonic aciduria and propionic aciduria. Pediatr Res 2009;66:91-95.
37. Fragaki K, Cano A, Benoist JF, et al. Fatal heart failure associated with CoQ10 and multiple OXPHOS deficiency in a child with propionic acidemia. Mitochondrion 2011;11:533-536.
38. Mardach R, Verity MA, Cederbaum SD. Clinical, pathological, and biochemical studies in a patient with propionic acidemia and fatal cardiomyopathy. Mol Genet Metab 2005;85:286-290.
39. Bhan AK, Brody C. Propionic acidemia: a rare cause of cardiomyopathy. Congest Heart Fail 2001;7:218-219.
40. Kraus JP, Spector E, Venezia S, et al. Mutation analysis in 54 propionic acidemia patients. J Inherit Metab Dis 2012;35:51-63.
41. Morton DH, Donnelly P, Duffy A, et al. Cardiomyopathy is common in the propionic acidemia variant PCCB c.1606A >G and can be prevented & reversed by metabolic therapy. Mol Genet Metab 2014;111:262-263.
42. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites inmouse hepatocellular carcinoma. Science 2007;317:477.
43. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8:1343-1346.
44. Miller DG, Trobridge GD, Petek LM, et al. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 2005;79:11434-11442.
45. Nakai H, Wu X, Fuess S, et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 2005;79:3606-3614.
46. Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest 2015 [Epub ahead of print] DOI: 10.1172/JCI79213